Objectives: To target pediatric dermatologists directly in order to evaluate their current demographics and the most important motivating factors that influenced their career choice. Pediatric dermatology is one of the pediatric subspecialties with an inadequate supply to meet current patient needs.

Study Design: A survey was designed to evaluate the training pathway, employment status, participation in teaching, and clinical practice characteristics of pediatric dermatologists. The survey was administered to attendants of the 2010 Society for Pediatric Dermatology annual meeting. Any remaining board certified pediatric dermatologists who had not previously responded were queried via Survey Monkey.

Results: There was a 71% response rate. The majority chose a career in pediatric dermatology early, often prior to starting a dermatology residency. The vast majority of respondents noted mentorship as the most important influence on their decision to pursue a career in pediatric dermatology. The most common obstacles cited by respondents were financial hardship and resistance of some dermatology programs to accept applicants previously trained in pediatrics.

Conclusions: Our survey provides evidence to support the importance of early exposure to the field and, most importantly, to committed pediatric dermatologists who can serve as mentors. This information may be helpful in approaching solutions to the workforce shortage in the field of pediatric dermatology.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpeds.2013.10.004DOI Listing

Publication Analysis

Top Keywords

pediatric dermatology
24
pediatric dermatologists
16
pediatric
10
dermatology
8
workforce shortage
8
career pediatric
8
understanding pediatric
4
dermatology workforce
4
shortage mentoring
4
mentoring matters
4

Similar Publications

Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over 52 weeks. This multicenter retrospective study included 96 adult patients diagnosed with severe AA from 11 Italian Dermatology Units.

View Article and Find Full Text PDF

Purpose/aim Of The Study: There is limited real-world evidence regarding the effectiveness and safety of dupilumab in Gulf countries. The study aimed to evaluate atopic dermatitis (AD) disease control in adult and adolescent patients (≥12 years) treated with dupilumab in Gulf countries.

Materials And Methods: This observational study included patients with moderate-to-severe AD who initiated dupilumab within 30 days.

View Article and Find Full Text PDF

To evaluate the long-term efficacy and safety of secukinumab in pediatric patients with generalized pustular psoriasis (GPP). A retrospective study was conducted from July 2021 to July 2024, including 10 children with GPP. Patients were divided into two age groups: children aged 0-3 years received 75 mg of secukinumab, while those aged 3-12 years received 150 mg.

View Article and Find Full Text PDF

Drug Extravasation in a Tertiary Referral Children Hospital: A Prospective Cohort Study.

Clin Pediatr (Phila)

January 2025

Pediatric Dermatology Division, Department of Pediatrics, Imam Hossein Children's Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.

Extravasation injuries are prevalent in pediatric hospitals and often result in tissue damage and extended hospital stays. However, limited data exist regarding risk factors for extravasation in children. This study aimed to identify these risk factors in pediatric patients receiving intravenous (IV) therapy.

View Article and Find Full Text PDF

Background/objective: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that typically occurs in childhood/infancy and is associated with complications like extracutaneous atopic morbidity. Providing systemic treatment for pediatric AD patients with unmet comprehensive medical needs remains challenging. We present a cohort study describing the efficacy and safety of dupilumab combined with topical calcineurin inhibitors (TCI) in children with moderate-to-severe atopic dermatitis under the age of 6 years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!